Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) has a beta value of 1.54 and has seen 1.29 million shares traded in the last trading session. The company, currently valued at $49.70M, closed the last trade at $1.15 per share which meant it gained $0.04 on the day or 3.60% during that session. The SLRX stock price is -204.35% off its 52-week high price of $3.50 and 45.22% above the 52-week low of $0.63. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.27 million shares traded. The 3-month trading volume is 1.39 million shares.
The consensus among analysts is that Salarius Pharmaceuticals Inc. (SLRX) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.08.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Sporting 3.60% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/24/21 when the SLRX stock price touched $1.15 or saw a rise of 4.17%. Year-to-date, Salarius Pharmaceuticals Inc. shares have moved 26.37%, while the 5-day performance has seen it change 4.55%. Over the past 30 days, the shares of Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) have changed 15.00%. Short interest in the company has seen 1.63 million shares shorted with days to cover at 1.66.
Wall Street analysts have a consensus price target for the stock at $5.00, which means that the shares’ value could jump 77.0% from current levels. The projected low price target is $5.00 while the price target rests at a high of $5.00. In that case, then, we find that the current price level is -334.78% off the targeted high while a plunge would see the stock gain -334.78% from current levels.
Salarius Pharmaceuticals Inc. (SLRX) estimates and forecasts
Figures show that Salarius Pharmaceuticals Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -26.28% over the past 6 months, with this year growth rate of 44.00%, compared to 18.00% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 20.00% and 20.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be -41.10%.
3 analysts offering their estimates for the company have set an average revenue estimate of $630k for the current quarter. 3 have an estimated revenue figure of $630k for the next quarter concluding in Dec 2021.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 60.50% over the past 5 years.
Salarius Pharmaceuticals Inc. is expected to release its next earnings report between November 09 and November 15 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Salarius Pharmaceuticals Inc. (NASDAQ:SLRX)’s Major holders
Insiders own 1.51% of the company shares, while shares held by institutions stand at 38.17% with a share float percentage of 38.76%. Investors are also buoyed by the number of investors in a company, with Salarius Pharmaceuticals Inc. having a total of 39 institutions that hold shares in the company. The top two institutional holders are Sio Capital Management, LLC with over 3.12 million shares worth more than $4.62 million. As of Mar 30, 2021, Sio Capital Management, LLC held 6.97% of shares outstanding.
The other major institutional holder is SilverArc Capital Management, LLC, with the holding of over 1.99 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $2.95 million and represent 4.45% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Mar 30, 2021, the former fund manager holds about 2.42% shares in the company for having 1.08 million shares of worth $1.6 million while later fund manager owns 0.24 million shares of worth $0.36 million as of Mar 30, 2021, which makes it owner of about 0.54% of company’s outstanding stock.